Construction has already started on the new facility, which will be approved and operational by June 2008.

Under this agreement, TTL will deliver a high-specification, modern facility that will expand Encap’s current R&D and production plant to over 40,000 ft2. The new facility also includes dedicated, high-containment suites that strengthen Encap’s integrated capability in formulation development, clinical and commercial manufacture of high-potency and cytotoxic compounds.

The expansion has been driven by escalating demand from worldwide Customers for the Company’s liquid-fill two-piece capsule technologies, facilities and know-how. Encap’s specialist encapsulation technologies are ideally suited for new product development and life-cycle extension. Liquid-fill encapsulation is one of the fastest growing sectors of the drug delivery market, increasing at a rate of 10-30% per annum. The technology offers many advantages including enhanced bioavailability, rapid formulation development, contained manufacturing and safe handling.